Regenxbio (RGNX) Share-based Compensation (2014 - 2025)

Regenxbio's Share-based Compensation history runs 12 years deep, the most recent figure standing at $8.4 million for Q4 2025.

• On a quarterly basis, Share-based Compensation fell 12.23% year-over-year to $8.4 million in Q4 2025; TTM through Dec 2025 was $35.5 million, a 7.83% decrease from a year earlier, with the FY2025 full-year figure at $47.7 million, down 20.1% from the prior year.
• Share-based Compensation declined to $8.4 million in Q4 2025 per RGNX's latest filing, from $9.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $65.6 million in Q2 2025 and bottomed at $8.3 million in Q4 2023.
• The 5-year median for Share-based Compensation is $9.8 million (2021), against an average of $12.5 million.
• Across the five-year window, Share-based Compensation decreased 14.31% in 2024 and soared 595.28% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $9.2 million in 2021, then advanced by 2.69% to $9.4 million in 2022, then retreated by 11.37% to $8.3 million in 2023, then increased by 14.44% to $9.5 million in 2024, then decreased by 12.23% to $8.4 million in 2025.
• Per Business Quant, the three latest RGNX Share-based Compensation figures stand at $8.4 million (Q4 2025), $9.0 million (Q3 2025), and $65.6 million (Q2 2025).